Construction-LBD (Constructional Apraxia in Alzheimer’s Disease (AD) and Lewy Body’s Dementia (LBD))

Overview

Alzheimer's disease (AD) and Lewy body's dementia (LBD) are two frequent neurodegenerative pathologies. They differ in their expression, their evolution but share same features which make their diagnosis uneasy. Constructional apraxia has been described in both disease.The underlying mechanisms have been less studied and could be different in AD and LBD. The definition of the constructional apraxia is purely descriptive and few models are inconclusive. It is admitted that drawing tasks involve visuo-perceptive and visuo-spatial abilities, executive functions and working memory as well as purely "constructive" skills. Regarding to different studies, visuo-perceptive abilities are more severely impaired in LBD than in AD and are considered as an early onset sign of the disease. Executive functions deficits are documented in AD and LDB and could contribute to the drawing impairment. It is possible to compensate the planning disorders in giving patient the best strategy to use. If drawing impairment persists, they should result of others mechanisms like visuo-perception, visuo-spatial or constructive deficits. The investigators suggest that giving the best planning strategy will help more AD patients who are supposed to fail in raison of an executive impairment, than the LDB group who is supposed to present visuo-perceptive deficits. An MRI will be proposed to study the cerebral areas involved in constructional apraxia.

Full Title of Study: “Constructional Apraxia in Alzheimer’s Disease (AD) and Lewy Body’s Dementia (LBD)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 2016

Interventions

  • Other: Rey figure test
  • Other: MRI

Arms, Groups and Cohorts

  • Experimental: Alzheimer’s disease (AD)
    • Rey figure test and MRI
  • Experimental: Lewy body’s dementia (LBD)
    • Rey figure test and MRI

Clinical Trial Outcome Measures

Primary Measures

  • Score obtained at the Rey figure test with a planning strategy help by LBD patients compared to the score obtained by AD patients.
    • Time Frame: At inclusion

Participating in This Clinical Trial

Inclusion Criteria

  • Alzheimer's disease or Lewy bodies dementia – ≥ 45 years – the cognitive impairment is mild to moderate – French speaker – a caregiver is present – An informed consent is signed by the patient and the p.i. Exclusion Criteria:

  • MRI contraindication – Other neurological disease (FTD, brain tumor, vascular disease…) – Psychiatric disease (Schizophrenia, major depression, psychotic disorders, melancholia…) – Patient who doesn't want to be informed in case of the discovery of an abnormality – View or audition deficits, or motor disability which can interfere with the cognitive testing – Patient participating to an exclusive protocol or in the period of exclusion – Pregnant woman – Person under an administrative or legal measure of liberty privation – Person under a legal measure of protection or under administrative supervision – Person unable to give his consent

Gender Eligibility: All

Minimum Age: 45 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Strasbourg, France
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Xavier DE PETIGNY, Docteur, 3 88 11 56 24, xavier.depetigny@chru-strasbourg.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.